Strides Shasun receives US FDA's EIR report for Bangalore facility

Strides Shasun Ltd receives Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA) for its oral dosage facility at Bangalore. “The company's oral dosage forms manufacturing site in Bangalore has received the Establishment Inspection Report, thereby confirming the closure of the inspection. The facility continues to be US FDA approved,” said Strides Shasun in a BSE filing today. The inspection of the facility was carried out by the US FDA in February 2016.
 
Strides Shasun’s KRS Gardens facility in Bangalore manufactures oral dosage forms including tablets, capsules (both hard gelatine and soft gelatine). The manufacturing plant supports important current and future submissions for the US market.